Basket | Login | Register

 
 
 
 

Estonia

2012: National Dementia Strategies (diagnosis, treatment and research)

Issues relating to medical treatment

The availability of medicines in general

Prescription drugs are generally reimbursed if they are on the “positive list”. People pay a subscription fee of approx. EUR 3.20 for pharmaceutical drugs reimbursed at 50% and a prescription fee of approx. EUR 1.27 for those reimbursed at a higher level of either 75% or 100%. The Health Insurance Fund pays up to EUR 12.79 for drugs reimbursed at the level of 50% and up to the reference price for those reimbursed at a higher level. The level of 75% reimbursement is increased to 90% for certain groups of people. This includes people who are disabled or retired. Over-the-counter drugs are not generally reimbursed[2].

The availability of Alzheimer treatments

All four AD drugs are authorised for use in Estonia.

Conditions surrounding the prescription and reimbursement of AD drugs

With the exception of Exelon (Donepezil), they are part of the reimbursement system and reimbursed at 50%.

Prescription and reimbursement

Donepezil

Rivastigmine

Galantamine

Memantine

Available

Yes

Yes

Yes

Yes

Reimbursed

No

Yes

Yes

Yes

Issues relating to research

Estonia is not involved in the EU Joint Programme – Neurodegenerative Disease Research (JPND) or in the Joint Action “Alzheimer Cooperative Valuation in Europe (ALCOVE)”.

[2] European Commission (2012): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland: Comparative tables

 

 
 

Last Updated: Tuesday 14 May 2013

 

 
  • Acknowledgements

    The above information was published in the 2012 Dementia in Europe Yearbook as part of Alzheimer Europe's 2012 Work Plan which received funding from the European Union in the framework of the Health Programme. Alzheimer Europe gratefully acknowledges the support it has received from the Alzheimer Europe Foundation for the preparation and publication of its 2012 Yearbook.
  • European Union
 
 

Options